for people ages 18 years and up (full criteria)
at Orange, California and other locations
study started
estimated completion



This study will evaluate the safety profile, tolerability, PK, PD, and preliminary efficacy of BMS-813160 alone or in combination with either chemotherapy or nivolumab in participants with metastatic colorectal and pancreatic cancers.

Official Title

A Phase 1b/2 Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors


Colorectal Cancer Pancreatic Cancer Leucovorin Gemcitabine Paclitaxel Fluorouracil Irinotecan Nivolumab BMS-813160 Nab-paclitaxel 5-fluorouracil (5-FU) Monotherapy


For people ages 18 years and up

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit

Inclusion Criteria:

  • Participants must have metastatic colorectal or pancreatic cancer
  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤1
  • Ability to swallow pills or capsules
  • All participants will be required to undergo mandatory pre and on-treatment biopsies
  • Adequate marrow function
  • Adequate other organ functions
  • Ability to comply with study visits, treatment, procedures, PK and PD sample collection, and required study follow-up

Exclusion Criteria:

  • Histology other than adenocarcinoma (neuroendocrine or acinar cell)
  • Suspected, known, or progressive CNS metastases (Imaging required only if participants are symptomatic)
  • Participants with active, known or suspected autoimmune disease
  • Participants with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study treatment administration
  • Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected treatment-related pulmonary toxicity
  • Prior treatment with CCR2 and/or CCR5 inhibitors, PD-1, PD(L)-1 or CTLA-4 antibodies
  • History of allergy to study treatments or any of its components of the study arm that participant is enrolling

Other protocol defined inclusion/exclusion criteria could apply


  • Uc Irvine Medical Center in progress, not accepting new patients
    Orange California 92868 United States
  • USC Norris Comprehensive Cancer Center in progress, not accepting new patients
    Los Angeles California 90033 United States
  • Usc/Norris Comprehensive Cancer Center in progress, not accepting new patients
    Los Angeles California 90033 United States


accepting new patients
Start Date
Completion Date
Bristol-Myers Squibb
Phase 1/2
Study Type
Last Updated